A Phase II, Randomised, Double-Blind, Placebo-Controlled Study Followed by a Continuing Open Label Study, to Verify the Efficacy and Safty of Intrathecal Administration of KP-100IT using NP022 in Subjects with Amyotrophic Lateral Sclerosis (ALS)
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Hepatocyte growth factor (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- 13 Nov 2017 Status changed from recruiting to completed.
- 10 Jun 2016 Status changed from not yet recruiting to recruiting.
- 23 May 2016 New trial record